Click here for slides on this topic


Obesity

A condition characterized by an excessive amount of body fat. Obesity is a risk factor for type 2 diabetes.


The following content matched the glossary term: Obesity

AHA ADA prevention of CVD in T2D - Metabolic Bariatric Surgery for Weight Management

Top

Summary of recommendations for bariatric surgery for obese patients from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AHA ADA prevention of CVD in T2D - Pharmacologic Therapy for Weight Management

Top

Summary of pharmacologic therapy options for weight loss from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AACE 2015 guidelines Obesity Management

Top

Summary of the obesity treatment algorithm, including pharmacologic therapy and bariatric surgery, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

Endocrine Society obesity clinical practice guideline

Top

Summary of guidelines for managing obesity with pharmacologic therapy from the Endocrine Society.

NDEI.org Expert Commentary Phentermine-topiramate for weight loss in type 2 diabetes Silvio Inzucchi

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "Weight loss remains a great challenge for our patients, especially those with diabetes."

Weight-loss therapy in type 2 diabetes effects of phentermine and topiramate extended-release

Top

Exclusive! Expert diabetes blog post from Silvio Inzucchi, MD. Garvey WT, Ryan DH, Bohannan NJV, et al. Weight loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309-3316.

Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Espeland MA, Glick HA, Bertoni A, et al; for the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: The Action for Health in Diabetes. Diabetes Care. 2014;37:2548-2566.

Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study

Top

Cheng S, Claggett B, Correia AW, et al. Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study. Circulation. 2014;130:820-828.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Obesity Slides Found: 248
Beneficial Lifestyle Changes: Physical Activity Improves Glycemic Control
Type 2 Diabetes in Youth A Growing Problem
Prevalence of the Insulin Resistance Syndrome (NCEP) in the US Population
Risk Factors for Conversion to Diabetes in Mexican Americans
Opportunities and Challenges for Care Extended Family Roles
Global Prevalence of Obesity Among Adults
Energy Balance: Intake vs Expenditure
Energy Balance: Afferent and Efferent Signals
Energy Balance: Molecules That Regulate Eating and Energy Expenditure
Energy Balance: Molecules That Regulate Eating and Energy Expenditure (cont’d)
Acute Effect of Peptide YY3-36 on Food Intake
Rare Monogenic Causes of Human Obesity
Homozygous Mutation in Melanocortin-4 Receptor Gene
Single-Gene Syndromic Forms of Obesity
Increased Fructose Consumption and the Rise in Obesity
Depression Predicts Obesity: Prospective Data
Obesity Predicts Depression: Prospective Data
Television Watching and Risk of Obesity
Quality of Life for Obese Children and Adolescents
Cancer Mortality According to Body Mass Index
Assessing Risk: BMI and Waist Circumference
Assessing Risk: Waist Circumference
Assessing Risk: Is Measurement of Waist Circumference Necessary?
Assessing Risk for Morbidity and Mortality: Comorbidities and Other Risk Factors
NHLBI Guidelines for Treatment of Obesity
Physician Attitudes Toward Obese Patients
Behavior Therapy: Definition and Techniques
Behavior Therapy: Self-Monitoring
Behavior Therapy: Stress Management
Behavior Therapy: Social Support
Behavior Therapy: Efficacy
Behavior Therapy: Evolution of Results
Medical Nutrition Therapy: Basic Considerations
Medical Nutrition Therapy: Additional Considerations
Low-Carbohydrate Diet vs Low-Fat Diet
FTC Guidelines for Commercial Weight Loss Programs
Effect of Physical Activity on Weight Loss: Nurses’ Health Study II
Adiponectin and CRP Levels in Healthy Obese Women
Agents That Alter Metabolism
Malabsorptive Surgery: Outcomes
Bariatric Surgery: Gastrorestrictive Procedures
Gastrorestrictive Surgery: Outcomes
Laparoscopy and Liposuction
Bariatric Surgery: Conclusions
Beneficial Lifestyle Changes: Physical Activity Improves Glycemic Control
CARDIA: Fast-Food Frequency and Insulin Resistance
Waist Circumference, TG Levels Predict Future MetS in 18- to 19-Yr-Old Females
INTERHEART: Waist-to-Hip Ratio Is a Better Predictor for MI Than BMI
Prevalence of Overweight/Obesity Among US Adults (NHANES 2003-2004)
Prevalence of Overweight/Obesity Among US Adults by Sex/Ethnicity (NHANES 2003-2004)
Cardiovascular Mortality in Patients With Coronary Artery Disease by BMI
Plasticity of Islets: Experimental Increase in Beta-Cell Mass in Response to IR
Type 2 Diabetes: Pathogenesis in a Nutshell
Beta-Cell Mass in Normal Patients and Patients With Diabetes: Autopsy Study
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
IRAS: Risk of Type 2 Diabetes by Food-Pattern Score and Obesity Status
Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
BLOOM-DM: Design
BLOOM-DM: Primary and Secondary Endpoints
BLOOM-DM: Subject Profile
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥5% Reduction in Baseline Body Weight
BLOOM-DM Co-Primary Endpoint: Change in Body Weight
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥10% Reduction in Baseline Body Weight
BLOOM-DM: Secondary Endpoints
BLOOM-DM: Adverse Events
Obesity Trends Among US Adults
NHANES: Obesity Prevalence and BMI Trends Among US Adults
NHANES: Age-Adjusted Obesity Prevalence Among US Adults Aged ≥20 Years, 2009-2010
NHANES: Age-Adjusted Obesity Prevalence Among US Men Aged ≥20 Years by Race/Ethnicity, 2009-2010
NHANES: Age-Adjusted Obesity Prevalence Among US Women Aged ≥20 Years by Race/Ethnicity, 2009-2010
NHANES: Age-Adjusted Combined Obesity and Overweight Prevalence Among US Adults Aged ≥20 Years, 2009-2010
NHANES: Age-Adjusted Combined Obesity and Overweight Prevalence Among US Men Aged ≥20 Years by Race/Ethnicity, 2009-2010
NHANES: Age-Adjusted Combined Obesity and Overweight Prevalence Among US Women Aged ≥20 Years by Race/Ethnicity, 2009-2010
NHANES: Age-Adjusted Obesity and Overweight Prevalence Stratified by BMI and Race/Ethnicity Among US Adults Aged ≥20 Years, 2009-2010
NHANES: Obesity and BMI Trends Among US Adults Aged ≥20 Years, 1999-2010
Obesity and Overweight Statistics
Health Consequences of Obesity
NHANES: Obesity Prevalence and BMI Trends Among US Children and Adolescents
NHANES: Obesity Prevalence Among US Children and Adolescents Aged 2-19 Years, 2009-2010
NHANES: Obesity Prevalence Among US Boys Aged 2-19 Years by Race/Ethnicity, 2009-2010
NHANES: Obesity Prevalence Among US Girls Aged 2-19 Years by Race/Ethnicity, 2009-2010
NHANES: Obesity and BMI Trends Among US Children and Adolescents, 1999-2010
Medical Comorbidities Associated with Obesity
Association Between Obesity and Comorbidities
Aggregate Years of Life Lost Due to Obesity, 2008
Secondary Causes of Obesity
Environmental Factors that Promote Obesity
Nonpharmacologic Treatments for Obesity
Bariatric Surgery for Obesity
JUPITER Analysis: Conclusions
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Glycemic Control Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Operative Safety, Waist Circumference
AusDiab Substudy: Design
AusDiab Substudy: Results
AusDiab Substudy: Physical Health Component Summary (PCS) Results
AusDiab Substudy: Mental Health Component Summary (MCS) Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Additional Parameters
SOS Analysis: Design
SOS Analysis: Mean Baseline Characteristics
SOS Analysis: Rate of Diabetes Incidence
SOS Analysis: Rate of Diabetes Incidence by Subgroup
SOS Analysis: Interaction Between Risk Factors and Treatment
SOS Analysis: Sensitivity Analyses; Adverse Events
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Rates Among Normal and Overweight/Obese Subjects with Diabetes
Look AHEAD: 1-Year Interim Results
Look AHEAD at 1 Year: Interventions
Look AHEAD at 1 Year: Change in Body Weight
Look AHEAD at 1 Year: Change in Fitness Levels
Look AHEAD at 1 Year: Additional Results
Look AHEAD: Lifestyle Interventions
Look AHEAD: 4-Year Data Analysis
Look AHEAD at 4 Years: Weight Reduction
Look AHEAD at 4 Years: Percent Weight Reduction and Gain
Look AHEAD at 4 Years: Weight Reduction By Subgroup, Insulin Use
Look AHEAD at 4 Years: Weight Maintenance
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
SOS Post-hoc Analysis: Effect of Bariatric Surgery on CV Events
Guidelines for Children and Adolescents With Type 2 Diabetes: Weight Loss, Diet (1 of 2)
Comorbidities in Children and Adolescents With Type 2 Diabetes: Obesity-Related Medical Conditions
Look AHEAD: Continuous, Sustained Type 2 Diabetes Remission
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
ESH/ESC Hypertension Guidelines: Individuals at Higher CV Risk
ESH/ESC Hypertension Guidelines: Physical Examination
STAMPEDE Metabolic Substudy: A1C Improvement in All Groups at 24 Months
STAMPEDE Metabolic Substudy: Greater Reduction in Truncal Fat with Gastric Bypass Vs Sleeve Gastrectomy
STAMPEDE Metabolic Substudy: Greater Increases in Insulin Sensitivity, Beta-Cell Function with Gastric Bypass
STAMPEDE Metabolic Substudy: Design
EQUATE: Greater Weight Loss With Phentermine/Topiramate ER Vs Placebo, Phentermine, & Topiramate ER
EQUATE: Achievement of At Least 5% Weight Loss
LABS-2: 3-Yr Weight Loss After Bariatric Surgery
LABS-2: 3-Yr Mortality After Bariatric Surgery
LABS-2: 3-Yr Remission & Incidence of Cardiometabolic Outcomes After Bariatric Surgery
Long-Term Obesity Medications: At Least 5% Weight Loss After 1 Year
EQUATE: Achievement of At Least 10% Weight Loss
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
AHA/ACC/TOS Obesity Guidelines: CVD and All-Cause Mortality With High BMI
AHA/ACC/TOS Obesity Guidelines: Dietary Strategies for Weight Loss
AHA/ACC/TOS Obesity Guidelines: Recommended Diets for Weight Loss in Overweight and Obese Adults
AHA/ACC/TOS Obesity Guidelines: High-Intensity, Onsite Lifestyle Intervention
AHA/ACC/TOS Obesity Guidelines: Comprehensive Lifestyle Interventions
AHA/ACC/TOS Obesity Guidelines: Bariatric Surgery Outcomes
AHA/ACC/TOS Obesity Guidelines: Predictors of Weight Loss With Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Bariatric Surgery Complications
AHA/ACC/TOS Obesity Guidelines: Complications Seen With Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Identifying Candidates for Weight Loss
AHA/ACC/TOS Obesity Guidelines: Counseling on Benefits of Weight Loss
AHA/ACC/TOS Obesity Guidelines: Prescribing Diets for Weight Loss
AHA/ACC/TOS Obesity Guidelines: Lifestyle Intervention for Weight Loss in Adults
AHA/ACC/TOS Obesity Guidelines: Lifestyle Intervention for Weight Maintenance in Adults
AHA/ACC/TOS: Candidates for Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Assessing BMI & Determining Readiness for Lifestyle Changes
AHA/ACC/TOS Obesity Guidelines: Treatment Algorithm for Overweight & Obese Adults Committed to Weight Loss
AHA/ACC/TOS Obesity Guidelines: Treatment Algorithm for Achieving & Maintaining Weight Loss
AHA/ACC/TOS Obesity Guidelines: Efficacy of Weight Loss Interventions
STAMPEDE: A1C Less Than or Equal to 6.0 Percent at 3 Yrs With Bariatric Surgery Vs Medical Therapy
Type 2 Diabetes Alzheimer Disease | NDEI
Bariatric Surgery Type 2 Diabetes Remission SOS Study | NDEI
Bariatric Surgery Type 2 Diabetes Complications SOS Study | NDEI
Bariatric Surgery Type 2 Diabetes Weight Loss | NDEI
SOS Study Bariatric Surgery Type 2 Diabetes Design | NDEI
ARIC Cardiovascular Risk Trends | NDEI
Hypertension Obesity Diabetes CVD Risk Factors in ARIC Study | NDEI
CVD Risk Trends ARIC Gender | NDEI
Trends in CVD Risk ARIC Study | NDEI
CVD Risk Trends By Race ARIC Study | NDEI
Look AHEAD Impact of Intensive Lifestyle Health Costs Diabetes Slide | NDEI
Look AHEAD Intensive Lifestyle Reduces 10-Yr Diabetes Health Costs | NDEI
Does Early Weight Loss With Lorcaserin Predict Outcomes Obesity | NDEI
5% Weight Loss With Lorcaserin Predicts 1-Year Outcomes Obesity | NDEI
5% Weight Loss at 1 Year With Lorcaserin Vs Placebo Obesity | NDEI
10% Weight Loss at 1 Year With Lorcaserin Vs Placebo Obesity | NDEI
Early Weight Loss With Lorcaserin Predicts 1-Yr Response Obesity | NDEI
Lorcaserin Phentermine Overweight Obesity Adverse Events | NDEI
Lorcaserin + Phentermine Weight Loss Overweight Obese | NDEI
Lorcaserin + Phentermine Overweight Obese Weight Loss | NDEI
SCALE Obesity & Prediabetes Study Liraglutide Overweight Obesity | NDEI
SCALE-Diabetes Liraglutide Weight Loss QoL Obesity/Overweight | NDEI
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
Preventing Weight Gain in Adolescents Digital Interventions Obesity | NDEI
Trends in Added Sugar Intake Among US Children and Adults | NDEI
BLOOM-DM Lorcaserin Glycemic Effect Type 2 Diabetes | NDEI
Teen-LABS CVD Risk in Adolescents Undergoing Bariatric Surgery | NDEI
AMOS Study Bariatric Surgery for Adolescents With Severe Obesity | NDEI
Bariatric Surgery & Long-Term Survival in Veterans Severe Obesity | NDEI
Effect of Bariatric Surgery on Type 2 Diabetes Medication Use | NDEI
Safety Bariatric Surgery for BMI <35 at 1 Year
US Adults Who May Be Candidates for Obesity Therapy | NDEI
Does Weight Loss With Naltrexone/Buproprion + Lifestyle Differ Among African American and Caucasian Subjects
Changes in Obesity Duration Over Time Among US Adults
Efficacy of Phentermine + Topiramate for Weight Loss With BMI ≥35
Greater Weight Loss With Phentermine + Topiramate Obesity Type 2 Diabetes | NDEI
Phentermine + Topiramate Safety Obesity Type 2 Diabetes | NDEI PPT
Phentermine Plus Topiramate Weight Loss Obesity Type 2 Diabetes | NDEI
EMPA-REG Blood Pressure Lowering With Empagliflozin Type 2 Diabetes Hypertension | NDEI
EMPA-REG Blood Pressure Reductions With Empagliflozin SGLT2 | NDEI PPT
EMPA-REG A1C & Weight Loss Empagliflozin SGLT2 Type 2 Diabetes | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
EMPA-REG BP: A1C, BP, & Weight Reduction With Empagliflozin in Type 2 Diabetes & Hypertension Clinical Significance for HCPs
Does Bariatric Surgery Influence Type 2 Diabetes Development PPT | NDEI
Incidence of Type 2 Diabetes After Bariatric Surgery Obesity PPT | NDEI
Management of Obesity Endocrine Society Guidelines 2015 PPT | NDEI
Treatment Strategies for Long-Term Weight Loss ENDO Obesity Guidelines | NDEI
Match Weight Loss Medications to Patient Endocrine Society Obesity Guidelines | NDEI
Efficacy & Safety of Weight Loss Medications Endocrine Society Obesity Guidelines | NDEI
Endocrine Society Obesity Guidelines Dosing for Obesity Treatment PPT | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
Endocrine Society Obesity Guidelines Phentermine Long-Term Use PPT | NDEI
ACCORD BP Post-hoc Analysis: Primary Outcome by Waist/Height Quartiles
SCALE Obesity & Prediabetes Trial Liraglutide GLP-1 Design PPT | NDEI
SCALE Trial FPG Liraglutide Vs Placebo in Obese Subjects PPT | NDEI
SCALE Obesity & Prediabetes Liraglutide Blood Pressure PPT | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide Hypoglycemia PPT | NDEI
Low-Fat Diet Better Than Low-Carb for Weight Loss in Obesity ENDO2015 | NDEI
RYGB Vs Sleeve Gastrectomy for Weight Loss & Glycemic Control ENDO2015 | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI
Weight Loss With Liraglutide 3 mg Obese With Prediabetes SCALE ENDO2015 | NDEI
Safety & Efficacy of Lorcaserin + Phentermine Among Overweight or Obese Subjects
AACE 2015 Diabetes Guidelines Overweight/Obesity Treatment Algorithm | NDEI
AACE 2015 Diabetes Guidelines Obesity Management BMI Bariatric | NDEI
ACCORD BP Post-hoc Analysis: Design
ACCORD BP Post-hoc Analysis: Secondary Outcomes by Waist/Height Quartiles
ACCORD BP Post-hoc Analysis:Outcomes by Treatment Group, Waist-to-Height Quartiles
Study Examines Overall Safety of Bariatric (Metabolic/Diabetes) Surgery
Type 2 Diabetes Risk Factors US Preventive Services Guidelines | NDEI
Screening for Type 2 Diabetes & Prediabetes in Asymptomatic Individuals
Diabetes Comorbities ADA Guidelines | NDEI PPT
Fatty Liver Disease Is A Diabetes Comorbidity ADA Guidelines | NDEI
Sleep Apnea Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cancer Is A Diabetes Comorbidity ADA Guidelines | NDEI PPT
Fractures Are A Diabetes Comorbidity ADA Guidelines | NDEI
Low Testosterone Is A Comorbidity of Diabetes ADA Guidelines | NDEI
Hearing Impairment Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cognitive Impairment & Diabetes ADA Guidelines Slide | NDEI
ADA Obesity Management Guidelines in Patients With Type 2 Diabetes | NDEI
Treatment for Overweight & Obesity in Type 2 Diabetes ADA Guidelines | NDEI
Obesity Treatment Options Type 2 Diabetes ADA Guidelines | NDEI PPT
Statin Therapy in Type 2 Diabetes ADA Guidelines 2016 | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
Lifestyle Changes for Obesity Management ADA Guidelines | NDEI PPT
Type 2 Diabetes & Prediabetes Screening ADA Guidelines | NDEI PPT
Metabolic Surgery for Type 2 Diabetes Treatment Guidelines PPT | NDEI
Patient Selection Metabolic Surgery for Type 2 Diabetes Treatment Guidelines | NDEI
Metabolic Surgery Procedures for Treating Type 2 Diabetes Guidelines | NDEI